Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Study Evaluating the Tolerability of Bifeprunox in Healthy Subjects
This study is ongoing, but not recruiting participants.
Sponsored by: Wyeth
Information provided by: Wyeth
ClinicalTrials.gov Identifier: NCT00581451
  Purpose

Safety and Tolerability study in healthy volunteers


Condition Intervention Phase
Healthy
Drug: bifeprunox
Phase I

Drug Information available for: Bifeprunox Bifeprunox mesylate
U.S. FDA Resources
Study Type: Interventional
Study Design: Randomized, Double Blind (Subject, Caregiver, Investigator), Single Group Assignment, Safety Study
Official Title: A 3-Part, Randomized, Multiple-Dose, Sequential Design Study of Bifeprunox in Healthy Subjects in Order to Establish a Titration Regimen With an Improved Tolerability Profile

Further study details as provided by Wyeth:

Primary Outcome Measures:
  • Tolerability [ Time Frame: 28 days ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Safety [ Time Frame: 28 days ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 144
Study Start Date: October 2007
Estimated Study Completion Date: December 2008
Estimated Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
A: Experimental
bifeprunox 25 day
Drug: bifeprunox
oral tablet once daily
B: Experimental
bifeprunox 14 day
Drug: bifeprunox
oral tablet once daily
C: Experimental
bifeprunox 14 day
Drug: bifeprunox
oral tablet once daily
D: Experimental
bifeprunox 9 day
Drug: bifeprunox
oral tablet once daily

  Eligibility

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion criteria:

  • Healthy male 18-50 years
  • Nonlactating female 18-50 years
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00581451

Sponsors and Collaborators
Wyeth
Investigators
Study Director: Medical Monitor Wyeth
  More Information

Responsible Party: Wyeth ( Wyeth (Registry Contact: Clinical Trial Registry Specialist) )
Study ID Numbers: 3168A2-1005
Study First Received: December 21, 2007
Last Updated: December 26, 2007
ClinicalTrials.gov Identifier: NCT00581451  
Health Authority: United States: Food and Drug Administration

Keywords provided by Wyeth:
inpatient ascending dose study to evaluate safety and tolerabi

Study placed in the following topic categories:
Healthy

ClinicalTrials.gov processed this record on January 13, 2009